Regulus Therapeutics Inc.
RGLS
Classificação em ações
#17334
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Preço da ação
$8.16
Última sincronização: 2025-06-26
Valor de mercado
$234.57M
Variação (1 dia)
0.00%
Variação (1 ano)
-56.96%
País
US
Negociar Regulus Therapeutics Inc. (RGLS)
Categoria
Healthcare
Receita da Regulus Therapeutics Inc. (RGLS)
Receita em Mar 2024 TTM: $219.60M
De acordo com os últimos relatórios financeiros da Regulus Therapeutics Inc., a receita atual da empresa (TTM) é $219.60M. Em 2022, a empresa obteve uma receita de $298.49M um aumento em relação a a receita do ano 2021, que foi de $204.23M. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Regulus Therapeutics Inc. de 2002 a 2026
Receita no final de cada ano
| Ano | Receita | Alterar |
|---|---|---|
| 2026 (TTM) | $219.60M | -16.63% |
| 2023 | $263.41M | -11.75% |
| 2022 | $298.49M | 46.15% |
| 2021 | $204.23M | -48.83% |
| 2020 | $399.10M | 395.72% |
| 2019 | $80.51M | -8.35% |
| 2018 | $87.84M | 9.61% |
| 2017 | $80.14M | 53.12% |
| 2016 | $52.34M | -54.62% |
| 2015 | $115.34M | 49.00% |
| 2014 | $77.41M | -27.79% |
| 2013 | $107.21M | 56.55% |
| 2012 | $68.48M | -47.51% |
| 2011 | $130.46M | 12.11% |
| 2010 | $116.37M | 0.16% |
| 2009 | $116.18M | 16.36% |
| 2008 | $99.85M | 10.24% |
| 2007 | $90.57M | 29.80% |
| 2006 | $69.78M | 640.17% |
| 2005 | $9.43M | -68.37% |
| 2004 | $29.80M | 54.60% |
| 2003 | $19.28M | 9.63% |
| 2002 | $17.58M | 0.00% |
Receita de empresas similares ou concorrentes
| Empresa | Receita | Diferença de Receita | País |
|---|---|---|---|
| $12.62B | 5,648.72% |
US
|
|
| $2.23B | 914.56% |
US
|
|
| $15.74B | 7,069.48% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 2,641.91% |
NL
|
